(Senrebotase) - _专利_临床

概要

基本信息

药物类型

酶

别名

TEM

靶点-

作用机制

可溶性NSF附着蛋白受体拮抗剂

治疗领域

神经系统疾病泌尿生殖系统疾病

在研适应症-

非在研适应症

疱疹后神经痛膀胱过度活动症尿失禁

原研机构

Health Protection Agency Porton Down1

在研机构-

非在研机构

Health Protection Agency Porton Down1Allergan Ltd. (Ireland)

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 432335249

来源: *****

Sequence Code 432335248

来源: *****

关联

5

项与 Senrebotase 相关的临床试验

NCT01678924 / Terminated临床2期

A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).

开始日期2013-01-01

申办/合作机构

Allergan Ltd. (Ireland)

EUCTR2010-021718-41-NL / Not yet recruitingN/A

A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of theSafety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder andUrinary Incontinence

开始日期2011-03-03

申办/合作机构

Allergan Ltd. (Ireland)

EUCTR2010-020977-18-DE / Not yet recruitingN/A

A Multicenter, Double-blind, Randomized, Placebo-controlled, Repeat Treatment (two cycle) Study of the Safety and Efficacy of AGN-214868 in Patients with Postherpetic Neuralgia

开始日期2010-11-02

申办/合作机构

Allergan Ltd. (Ireland)

100 项与 Senrebotase 相关的临床结果

登录后查看更多信息

100 项与 Senrebotase 相关的转化医学

登录后查看更多信息

100 项与 Senrebotase 相关的专利（医药）

登录后查看更多信息

468

项与 Senrebotase 相关的文献（医药）

2024-04-01·Heliyon

Comparison of local excision and total mesorectal excision for rectal cancer: systematic review and meta-analysis of randomised controlled trial

Article

作者: Meng, Zan ; Liu, Zehong

To report the first and largest systematic review and meta-analysis of radomised controlled trials (RCTs) to compare the efficacy and safety of transanal endoscopic microsurgery (TEM) and total mesorectal excision (TME) for rectal cancer for perioperative and oncological outcomes. Methods: We conducted a systematic literature retrieval via PubMed, Embase, Web of Science, and Cochrane until December 2022 for RCTs which evaluated the efficacy and/or safety between TEM and TME for rectal cancer. Outcomes included operative time, blood loss, transfusion rates, hospital stay, complication rates, recurrence rates, and mortality. Results: A total of 5 RCTs involving 545 patients (272 TEM versus 273 TME) were included for the meta-analysis. There were no significant differences between the two groups for age, gender, and distance from lower border of tumor to anal verge. Meta-analysis found that the TEM group was significantly favorable than the TME group for blood loss (WMD: 172.01; 95 % CI: 212.78, -131.24; P < 0.00001), hospital stay (WMD: 2.58; 95 % CI: 3.01, -2.16; P < 0.00001), operative time (WMD: 81.86; 95 % CI: 87.51, -76.21; P < 0.00001) and transfusion rates (RR: 0.05; 95 % CI: 0.01, 0.38; P = 0.004). The complication rates (RR: 0.60; 95 % CI: 0.32, 1.11; P = 0.10), recurrence rates (RR: 1.10; 95 % CI: 0.66, 1.83; P = 0.72), and mortality (RR: 1.23; 95 % CI: 0.67, 2.26; P = 0.51) were similar in the two groups. Conclusions: TEM was an effective and safe approach with advantages in perioperative outcomes compared with TME approach. Caution should be exercised in interpreting the differences in surgical complications between TEM and TME group due to significant heterogeneity and instability.

2024-04-01·Journal of Ethnopharmacology

Potent anti-angiogenic component in Kaempferia galanga L. and its mechanism of action

Article

作者: Tian, Haiyan ; Niu, Naxin ; Li, Yaolan ; Huang, Weihuan ; Tan, Ying ; Zheng, Nianjue

ETHNOPHARMACOLOGICAL RELEVANCETraditionally, the roots of Kaempferia galanga has been used to treat high blood pressure, chest pain, headache, toothache, rheumatism, indigestion, cough, inflammation and cancer in Asia. Nevertheless, most of its pharmacological studies were focused on ethanolic extracts and volatile oils. The exact active chemical constituents and their underlying mechanisms are still poorly understood, especially towards its anti-cancer treatment. Inhibition of angiogenesis is an important atrategy to inhibit tumor growth. It has been reported that the low polar component of the plant possessed anti-angiogenic activity. Yet, the potent compound which is responsible for the effect and its molecular mechanism has not been reported.AIM OF THE STUDYTo determine the potent anti-angiogenic component in K.galanga and its mechanism of action.MATERIAL AND METHODSThe low polar components of the plant were concentrated using the methods of supercritical fluid extraction (SFE), subcritical extraction (SCE) and steam distillation (SD). The anti-angiogenic activity of the three extracts was evaluated using a zebrafish model. The content of the active compound in those extracts was determined with HPLC analysis. The in-vitro and in-vivo activity of the isolated compound was evaluated using human umbilical vein endothelial cells (HUVECs) model, the aortic ring assay and the matrigel plug assay, respectively. Its molecular mechanism was further studied by the western blotting assay and computer-docking experiments. Besides, its cytotoxicity on cancer and normal cell lines was evaluated using the cell-counting kit.RESULTSHPLC results showed that trans-ethyl p-methoxycinnamate (TEM) was the major component of the extracts. The extract of SFE showed the best effect as it has the highest content of TEM. TEM could inhibit vascular endothelial growth factor (VEGF)-induced viability, migration, invasion and tube formation in human umbilical vein endothelial cells (HUVECs) in vitro. Moreover, it inhibited VEGF-induced sprout formation ex vivo and vessel formation in vivo. Mechanistic study showed that it could suppress tyrosine kinase activity of the receptor of VEGF (VEGFR2) and alter its downstream signaling pathways. In addition, the molecular docking showed that the binding of TEM and VEGFR2 is stable, which mainly attributed to the non-covalent binding interaction. Beside, TEM possessed little toxicity to both cancer and normal cells.CONCLUSIONTEM is the major anti-angiogenic component present in K. galanga and its anti-angiogenic property rather than toxicity provides scientific basis for the traditional use of K. galanga in cancer treatment.

2024-04-01·Journal of Public Health Research

Traditional eye medicine practice and its determinant factors among ophthalmic patients in the West Bank

Article

作者: Ayed, Ahmad ; Atawi, Raghda ; Batran, Ahmad

Background: Traditional eye medicine (TEM) is becoming more widely used across the world. Depending on the drugs used, TEM usage can be considered harmful or innocuous. The therapy may induce infection or irreparable blindness in the already injured eye. The aim of the study was to determine the proportion of traditional eye medicine practices and associated factors among adult ophthalmic patients attending ophthalmic clinics in the governmental hospitals in the West Bank. Design and methods: A cross-sectional study conducted on 300 patients. The data was collected using a structured, self-administered questionnaire. Results: The results of the study revealed that 65.7% of people use TEM. The most common symptoms that necessitated the use of traditional eye practice were inflammatory symptoms of the eye (49.2%), blurred vision (15.7%), and allergic conjunctivitis (10.7%). The most common TEM used was tea (34.0%), followed by herbal products (25.4%) and vegetable slices (potato, cucumber, and onion) (14.7%). The most traditional eye treatment was the topical route (92.9%). The majority of prescribers of traditional eye practice were traditional healers (48.7%). Furthermore, the current study found that occupation and the income were predictors of using traditional eye practice among ophthalmic patients attending ophthalmic clinics in selected West Bank hospitals. Conclusion: The proportion of traditional eye medicine practice was high among ophthalmic patients in the West Bank. The predictors of using traditional eye treatment were occupation and the income. The most common TEM used was tea, followed by herbal products and vegetable slices (potato, cucumber, and onion).

100 项与 Senrebotase 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12626

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疱疹后神经痛	临床2期	美国	Allergan Ltd. (Ireland)	2010-06-01
疱疹后神经痛	临床2期	德国	Allergan Ltd. (Ireland)	2010-06-01
疱疹后神经痛	临床2期	德国	Allergan Ltd. (Ireland)	2010-06-01
疱疹后神经痛	临床2期	波兰	Allergan Ltd. (Ireland)	2010-06-01
疱疹后神经痛	临床2期	波兰	Allergan Ltd. (Ireland)	2010-06-01
疱疹后神经痛	临床2期	捷克	Allergan Ltd. (Ireland)	2010-06-01
疱疹后神经痛	临床2期	捷克	Allergan Ltd. (Ireland)	2010-06-01
疱疹后神经痛	临床2期	美国	Allergan Ltd. (Ireland)	2010-06-01
膀胱过度活动症	临床2期	-	Health Protection Agency Porton Down1	-
膀胱过度活动症	临床1期	-	Health Protection Agency Porton Down1	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2020	N/A	神经内分泌肿瘤	32	CAPTEM regimen with standard doses of CAP and TEM	製鏇艱廠襯鹹願衊壓廠(蓋積鹽夢夢遞鬱艱築製) = 15.6% of pts withdrawal due to toxicity, mainly related to hematological G3 網範選網積齋窪艱艱壓 (餘構憲艱衊鬱壓夢獵膚 ) 更多	-	2020-09-17
				CAPTEM regimen with reduced doses of TMZ
NCT01678924 (CTgov)	临床2期	疱疹后神经痛	280	AGN-214868 (AGN 214868 65µg)	選醖淵鏇壓範膚鹹糧艱(憲構遞齋鏇鏇夢夢齋襯) = 鹹醖艱蓋襯構鏇簾鬱廠壓艱簾壓衊遞積願壓廠 (蓋鏇鬱憲鏇醖築蓋壓淵, 醖淵獵積夢鬱憲憲繭壓 ~ 構顧鑰廠夢襯襯窪廠鏇) 更多	-	2020-01-07
				AGN 214868 (AGN 214868 32.5µg)	選醖淵鏇壓範膚鹹糧艱(憲構遞齋鏇鏇夢夢齋襯) = 鏇餘窪艱鬱齋襯範製壓壓艱簾壓衊遞積願壓廠 (蓋鏇鬱憲鏇醖築蓋壓淵, 艱繭襯製膚範壓網淵鏇 ~ 鬱遞製憲齋壓糧廠鏇廠) 更多
ASCO2015	N/A	晚期神经内分泌肿瘤一线	58	Capecitabine plus temozolomide (CAP-TEM)Capecitabine plus temozolomide (CAP-TEM)Capecitabine plus temozolomide (CAP-TEM)Capecitabine plus temozolomide (CAP-TEM)	(壓遞壓夢遞願觸衊鹽遞) = 網積鑰廠獵衊夢願觸憲糧壓艱糧鏇築餘壓構簾 (鹹餘積壓蓋淵顧範壓繭 ) 更多	-	2015-05-20
NCT01157377 (CTgov)	临床2期	尿失禁 \| 膀胱过度活动症	160	AGN-214868 (AGN-214868 Total Dose 500 ng)	鑰簾鏇構顧襯遞製鏇築(夢壓窪壓製鬱廠築餘鑰) = 選遞鹽範醖膚選範鹽鹹襯簾艱窪壓鏇廠蓋艱選 (簾築醖窪糧獵鹹願觸艱, 鹹鏇廠鹹餘顧築遞襯糧 ~ 鑰構淵製構遞鑰衊願願) 更多	-	2014-03-19
				AGN-214868 (AGN-214868 Total Dose 1000 ng)	鑰簾鏇構顧襯遞製鏇築(夢壓窪壓製鬱廠築餘鑰) = 夢築鹹鬱膚範鏇淵範築襯簾艱窪壓鏇廠蓋艱選 (簾築醖窪糧獵鹹願觸艱, 顧膚醖窪餘艱蓋廠觸鬱 ~ 積遞鬱簾簾構衊淵憲餘) 更多
ASCO_GI2014	N/A	晚期神经内分泌肿瘤一线	29	Capecitabine plus temozolomide (CAP-TEM)Capecitabine plus temozolomide (CAP-TEM)Capecitabine plus temozolomide (CAP-TEM)Capecitabine plus temozolomide (CAP-TEM)	(獵選淵築夢醖齋網餘範) = 窪構鬱鹹選壓艱鏇構糧餘顧遞膚齋遞鹽範網齋 (鹽淵獵製壓糧鏇鏇齋構, 53 ~ 87) 更多	-	2014-01-20
NCT01129531 (CTgov)	临床2期	疱疹后神经痛	294	AGN-214868 (AGN-214868 3.25 μg)	鹽糧顧艱鑰遞衊築襯築(築願顧積製蓋鹽積醖觸) = 窪範餘獵鑰夢醖繭壓膚範遞選繭憲獵鑰齋願選 (憲製鏇膚淵繭願窪膚簾, 築憲鏇願顧淵網醖鹹鬱 ~ 網鏇繭鏇壓範觸壓積壓) 更多	-	2013-11-15
				AGN-214868 (AGN-214868 16.25 μg)	鹽糧顧艱鑰遞衊築襯築(築願顧積製蓋鹽積醖觸) = 鏇構襯構製廠觸鏇繭夢範遞選繭憲獵鑰齋願選 (憲製鏇膚淵繭願窪膚簾, 範獵襯繭醖簾糧製夢構 ~ 窪憲壓鬱構壓鏇網糧餘) 更多
ASCO2012	临床2期	难治性软组织肉瘤	383	A12 and TEM	(糧艱襯鑰醖鹽鹹衊構願) = 淵築網蓋積鬱顧顧願鏇窪積範淵簾鏇艱膚壓餘 (淵憲選膚艱壓鹹廠願觸 )	-	2012-05-20
ASCO2007	临床2期	黑色素瘤	167	Extended dosing (TEM 75 mg/m2)	(夢襯構窪膚獵醖窪鹹齋) = 憲壓構製膚鹽襯襯鏇鏇憲繭襯餘積艱顧憲範蓋 (鹽願壓窪廠襯鏇淵窪積, 11–30)	-	2007-06-20
				Standard dosing (TEM 150 mg/m2)	(夢襯構窪膚獵醖窪鹹齋) = 鏇構醖壓獵艱壓築鹹鬱憲繭襯餘積艱顧憲範蓋 (鹽願壓窪廠襯鏇淵窪積, 7–34)
ASCO2006	临床2期	黑色素瘤	167	SO + TEM (extended daily dosing)	(範淵餘觸築積膚鬱製鑰) = 製壓鏇鏇蓋鹹憲醖蓋齋鏇衊糧襯選願鹹夢壓醖 (願襯積襯艱憲膚製製鏇, 11–41)	-	2006-06-20
				SO + TEM (standard dosing)	(範淵餘觸築積膚鬱製鑰) = 壓醖壓艱範膚艱構鹹艱鏇衊糧襯選願鹹夢壓醖 (願襯積襯艱憲膚製製鏇, 3–56)